- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
- Oragenics, Inc. Files 10K and Provides Company Update
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
- Oragenics Announces Closing of Public Offering
- Oragenics Announces Pricing of Public Offering
- Oragenics Announces Proposed Public Offering
- Oragenics, Inc. Announces Leadership Transition
- Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
- Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.01 |
---|---|
High | 1.04 |
Low | 1.01 |
Bid | 1.01 |
Offer | 1.09 |
Previous close | 1.02 |
Average volume | 24.04k |
---|---|
Shares outstanding | 4.48m |
Free float | 3.44m |
P/E (TTM) | -- |
Market cap | 4.57m USD |
EPS (TTM) | -8.69 USD |
Data delayed at least 15 minutes, as of May 02 2024.
More ▼